Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Monkasho Not Intending to Abolish Department of Pharmacy
July 15, 2002
- Takara Bio Reshuffles Its Business Structure
July 15, 2002
- GLs for Epidemiological Studies Enforced
July 15, 2002
- Dainippon to Boost Overseas Sales to 7% in FY2006: President Miyatake
July 15, 2002
- DIAGNOSTIC NEWS IN BRIEF
July 15, 2002
- Takeda Expects SCOPE Results to Boost Sales of Candesartan
July 15, 2002
- MEDICAL DEVICE NEWS IN BRIEF
July 15, 2002
- Tsumura Studying Combination of Western, Oriental Medicine
July 15, 2002
- PhRMA Adopts Principles for Conduct of Clinical Trials
July 15, 2002
- E2B/M2 Trial Results Announced
July 15, 2002
- Bayer BP to Start Hemophilia Awards Program
July 15, 2002
- MCC Acquires IC-Vec of UK Engaged in Gene Therapy
July 15, 2002
- Diabetic Nephropathy Approved as New Indication of Irbesartan
July 15, 2002
- Nippon Kayaku to Invest in Reverse Proteomics Research Institute
July 15, 2002
- Losartan Reduces Risk of Cardiovascular Death, Disease
July 15, 2002
- BUSINESS NEWS IN BRIEF
July 8, 2002
- GL for Progressive Renal Disease Published by Korosho Study Group
July 8, 2002
- WORLD NEWS IN BRIEF
July 8, 2002
- Toyama Ties Up with Arrow of the UK to Develop Antifungals
July 8, 2002
- NCCRI, FeRx to Collaborate on Gene Therapy Research
July 8, 2002
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…